克拉斯
癌症研究
胰腺癌
癌症
结直肠癌
癌细胞
癌变
生物
医学
内科学
作者
Takahiro Nagashima,K. Inamura,Y. Nishizono,A. Suzuki,H. Tanaka,T. Yoshinari,Y. Yamanaka
标识
DOI:10.1016/s0959-8049(22)00881-4
摘要
Background: KRAS is one of the most frequently mutated oncogenes in various cancers. Among KRAS mutations, KRAS G12D is the most frequent driver mutation and is found in approximately 34% of pancreatic ductal adenocarcinoma (PDAC), 10% to 12% of colorectal cancer, 4% of lung adenocarcinoma and also in a subset of other solid tumors. However, there is no direct KRAS G12D-targeted inhibitors used in the clinical setting. Here, we identified ASP3082, a novel KRAS G12D degrader with high potency and selectivity.
科研通智能强力驱动
Strongly Powered by AbleSci AI